Clinical trials: CtDNA
Pancreas Cancer
Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy
For patients who have been diagnosed with pancreatic cancer that has not spread outside of the pancreas and nearby lymph nodes. The purpose of this research study is to understand if we are able to detect pancreatic cancer DNA in…
- Trial name
- NCT04616131
- Where
- 3 sites in United States
- Volunteers
- 500 people
- Sponsor
- Northwestern University
Rectal Cancer, Adenocarcinoma, Neoadjuvant Chemoradiation
Multicenter, Prospective, RCT：Investigation of Combined Modality Therapy for Locally Advanced Mid/Low Rectal Cancer.
At present, the combined modality treatment of preoperative neoadjuvant chemoradiotherapy (NCRT) followed by radical surgery has become the standard of care for the locally advanced mid/low rectal cancer, having been proved to…
- Trial name
- NCT03042000
- Testing
- non-NCRT, NCRT, capecitabine with oxaliplatin
- Volunteers
- 1,200 people
- Sponsor
- Peking Union Medical College Hospital
Colon Cancer, Deficient Mismatch Repair
ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer
This prospective, multicenter, single-arm phase II interventional study evaluates whether longitudinal circulating tumor DNA (ctDNA) monitoring can guide neoadjuvant immunotherapy and surgical decision-making in dMMR/MSI-H colon…
- Conditions
- Colon Cancer, Deficient Mismatch Repair, Microsatellite Instability-High (MSI-H)
- Trial name
- NCT07841236
- Testing
- PD-1 inhibitor, CTLA-4 inhibitor, ctDNA/MRD testing
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Fudan University
Lung Cancer
T790M Plasma Testing Methodology Comparison and Clinical Validation
The aim of this study is to evaluate concordance of T790M mutation plasma testing between the Cobas test and each of other platforms: Super-ARMS, digital PCR or NGS.
- Trial name
- ADELOS (NCT02997501)
- Testing
- T790M+ Testing, Baseline Visit Blood & Urine Testing, Baseline ECG
- Where
- 7 sites in China
- Volunteers
- 256 people
- Sponsor
- AstraZeneca
Stage I-III Breast Cancer
Circulating Tumor DNA Monitoring in Breast Cancer Undergoing Neoadjuvant Therapy
In the prospective, open, observational study, we aim to evaluate whether circulating tumor DNA (ctDNA) can be the marker of the response to neoadjuvant therapy in stage I-III breast cancer.
- Trial name
- NCT05649475
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
HPV, Oropharynx Cancer
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
This study will look at whether monitoring HPV ctDNA levels is an effective way to detect cancer relapse risk in people with HPV-OPC.
- Conditions
- HPV, Oropharynx Cancer, HPV-Related Carcinoma, HPV-Related Malignancy
- Trial name
- NCT05307939
- Testing
- HPV ctDNA Assay, MRI Studies, EORTC QLQ H&N 35 and C30
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Resectable Pancreatic Cancer
Surgery Impact on Circulating Tumor DNA in Pancreatic Cancer
Pancreatic cancer represents the fourth cause of death by cancer in western countries. The only curative treatment is surgery but this one is possible only in 10 to 15 % of cases.
- Trial name
- ICAPAC (NCT03435536)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 35 people
- Sponsor
- University Hospital, Toulouse
Ovarian Neoplasms, Carcinoma, Ovarian Epithelial
Blood-Based Minimal Residual Disease in Advanced Epithelial Ovarian Cancer After 1st Line Therapy
The purpose of this observational study is to learn if a specialized blood test can help predict whether advanced ovarian cancer will return after a patient's initial treatments are finished.
- Conditions
- Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Ovarian Cancer
- Trial name
- NCT07670962
- Testing
- Blood-based ctDNA minimal residual disease (MRD) test
- Volunteers
- 300 people
- Sponsor
- Asan Medical Center
Metastatic Colorectal Cancer ctDNA Surveillance
Using ctDNA Methylation to Monitor Metastatic Colorectal Cancer Treatment (PROMET)
Multi-center observational clinical study to evaluate the application value of ctDNA methylation monitoring in efficacy assessment and relapse prediction in patients diagnosed with recurrence or metastatic colorectal cancer…
- Trial name
- NCT07283575
- Testing
- Plasma ctDNA methylation profiling
- Where
- China
- Volunteers
- 497 people
- Sponsor
- Fudan University
NSCLC (Non-small Cell Lung Cancer), Squamous Lung Cancer With FGFR1 Amplification
Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer
Microlyvaq™ is a first-line, non-randomized, two-arm clinical trial in advanced non-small cell lung cancer (NSCLC). In both arms, patients receive a personalized multi-epitope vaccine (Microlyvaq™) on top of standard-of-care…
- Conditions
- NSCLC (Non-small Cell Lung Cancer), Squamous Lung Cancer With FGFR1 Amplification, Non-Squamous Non Small Cell Lung Cancer
- Trial name
- Microlyvaq™ (NCT07285434)
- Testing
- Microlyvaq™ (Personalized Multi-Epitope Immunotherapeutic)
- Where
- Greece
- Volunteers
- 90 people
- Sponsor
- Biogenea Pharmaceuticals Ltd.
Nonsmall Cell Lung Cancer
Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment
The purpose of this study is to determine whether it is feasible and safe to give research participants investigational treatment with durvalumab and tremelimumab after they have completed standard treatment for NSCLC and once…
- Trial name
- NCT04625699
- Testing
- Durvalumab, Tremelimumab
- Sponsor
- Catherine Shu
Lung Cancer (Diagnosis), Circulating Tumor Cell
Liquid Biopsy in Lung Cancer
The purpose of this study is to assess clinical utility of combined circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) in the diagnosis of primary lung cancer.
- Trial name
- NCT03479099
- Where
- South Korea
- Volunteers
- 111 people
- Sponsor
- Samsung Medical Center
Pancreatic Cancer
Observational Study of ctDNA in Resectable and Borderline Resectable Pancreatic Cancer
The purpose of this study is to collect information about treatment recommendations based on ctDNA testing and whether treatment changes based on ctDNA information result in better outcomes for patients with pancreatic cancer.
- Trial name
- NCT05379907
- Testing
- SIGNATERA™ ctDNA testing
- Where
- United States
- Sponsor
- Inova Health Care Services
Metastatic Colon Cancer
De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer
Background : In unresectable mCRC, a de-escalation strategy using maintenance or chemotherapy (CT) discontinuation in selected cases is considered as a valid option in non-progressive patients after a first-line induction of…
- Trial name
- DIAMOND (NCT06446557)
- Testing
- treatment adaptation guided by ctDNA variation, standard management
- Where
- France
- Volunteers
- 408 people
- Sponsor
- University Hospital, Rouen
Pancreatic Cancer, Circulating Tumor Cell
Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery
This study evaluates the clinical prognostic impact (on DFS and OS) of liquid biopsy guided treatment vs. standard of care (physicians choice) in localized pancreatic cancer (despite because of CA 19-9 levels and computed…
- Conditions
- Pancreatic Cancer, Circulating Tumor Cell, Predictive Cancer Model
- Trial name
- LIQUIPANC (NCT06391892)
- Testing
- Neoadjuvant chemotherapy instead of upfront surgery, Upfront surgery
- Where
- Austria
- Volunteers
- 100 people
- Sponsor
- Elisabethinen Hospital
Uveal Melanoma
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomarker.
- Trial name
- NCT06070012
- Testing
- Tebentafusp
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Diwakar Davar
Lung Carcinoma
Predictive Value of CEA and ctDNA in Lung Cancer Recurrence
The study aims to investigate the predictive value of CEA levels for postoperative recurrence in the highly sensitive CEA lung cancer patients and to explore whether the dynamic changes of postoperative CEA and MRD in this…
- Trial name
- NCT07170046
- Volunteers
- 100 people
- Sponsor
- Guangdong Provincial People's Hospital
Hepatocellular Carcinoma
Clinical Research on Dynamic Monitoring MRD Via Plasma ctDNA After Systemic Therapy of Hepatocellular Carcinoma
This study aims to combine biomarker characteristic atlas and ctDNA detection technology to establish a precise standard scheme for minimal residual diagnosis of liver cancer after surgery and systemic treatment.
- Trial name
- NCT06178809
- Where
- China
- Volunteers
- 475 people
- Sponsor
- Singlera Genomics Inc.
Lung Cancer Stage III
Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC
Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies.
- Trial name
- MRD-LUNG (NCT06111807)
- Testing
- ctDNA
- Where
- 6 sites in France, Germany and 1 more
- Volunteers
- 248 people
- Sponsor
- University Medical Center Groningen
Lung Cancer, EGFR Gene Mutation
Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)
This study plans to conduct ctDNA testing on EGFR mutation-positive stage II-IIIA (N1-N2) NSCLC patients after radical surgery (R0 resection).
- Conditions
- Lung Cancer, EGFR Gene Mutation, Minimal Residual Disease
- Trial name
- NCT06323148
- Testing
- Osimertinib, No adjuvant therapy
- Volunteers
- 226 people
- Sponsor
- Fudan University